DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of the Application
Claims 1-15 are pending and are examined herein.
Claim Rejections - 35 USC § 112
The following is a quotation of the second paragraph of 35 U.S.C. 112(b):
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 2-6, 10-11, 13 are rejected under 35 U.S.C. 112(b) or 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
Regarding claims 2-6, 10-11, 13, the phrase "preferably" renders the claim indefinite because it is unclear whether the limitations following the phrases are part of the claimed invention. See MPEP § 2173.05(d).
Claims 3-4 are rejected under 35 U.S.C. 112(b) or 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Specifically, claims 3-4 recite the limitation "the branched chain amino acids" in claim 1. There is insufficient antecedent basis for this limitation in the claims.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
The factual inquiries set forth in Graham vs John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).
Claims 1-15 are rejected under 35 U.S.C. 103(a) as being obvious over Giorgetti (WO 2019/021137, of record) in view of Guven et al. (WO 2018/191789).
The instant claims are directed to a method of treating an intestinal disease by administering leucine, isoleucine, valine, threonine, lysine, citric acid, succinic acid, malic acid, histidine, phenylalanine, methionine, tryptophan, and cysteine.
Giorgetti teaches a method of treating or preventing a mitochondrial dysfunction-related disease by administering a composition comprising leucine, isoleucine, valine, threonine, lysine, citric acid, succinic acid, malic acid, histidine, phenylalanine, methionine, tryptophan, and cysteine in the claimed amounts and weight ratios (claims 1-15 and pages 8-10). Further, amino acids preferably excluded by the composition are arginine, serine, proline, and alanine (page 11, lines 9-11).
However, Giorgetti fails to disclose the nexus between mitochondrial dysfunction and intestinal diseases.
Guven et al. teach that the inflammatory disorders, ulcerative colitis and Crohn’s disease, are associated with mitochondrial dysfunction (paragraph 0018 and claim 21).
Therefore, it would have been prima facie obvious to a person of ordinary skill in the art, at the time the claimed invention was made, to have administered the composition comprising the claimed amino acids, as taught by Giorgetti, to a patient suffering from ulcerative colitis and/or Crohn’s disease, as taught by Guven et al.
A person of ordinary skill in the art would have been motivated to treat a patient with ulcerative colitis and/or Crohn’s disease by administering a composition comprising the claimed amino acids because Giorgetti teaches that the claimed amino acid composition is useful in the treatment of a mitochondrial dysfunction-related disease. Since ulcerative colitis and Crohn’s disease are known mitochondrial dysfunction-related diseases, one of ordinary skill in the art would have had a reasonable expectation of success in treating these diseases by administering the claimed amino acid composition.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yong S. Chong whose telephone number is (571)-272-8513. The examiner can normally be reached Monday to Friday: 9 AM to 5 PM EST.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam Milligan, can be reached at (571)-270-7674. The fax phone number for the organization where this application or proceeding is assigned is (571)-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at (866)-217-9197 (toll-free).
/Yong S. Chong/Primary Examiner, Art Unit 1623